Literature DB >> 34826032

Blood-brain barrier dysfunction and myelin basic protein in survival of amyotrophic lateral sclerosis with or without frontotemporal dementia.

Jin-Yue Li1, Zheng-Yi Cai1, Xiao-Han Sun1, Dong-Chao Shen1, Xun-Zhe Yang1, Ming-Sheng Liu1, Li-Ying Cui2,3.   

Abstract

OBJECTIVE: We aim to investigate blood-brain barrier (BBB) dysfunction and myelin basic protein (MBP) in amyotrophic lateral sclerosis (ALS) with or without frontotemporal dementia (FTD) and further determine the effect of these factors on the survival of ALS.
METHODS: This was a retrospective study of 113 ALS patients, 12 ALS-FTD patients, and 40 disease controls hospitalized between September 2013 and October 2020. CSF parameters including total protein (TP), albumin (Alb), immunoglobulin-G (IgG), and MBP were collected and compared between groups. The CSF-TP, CSF-Alb, CSF-IgG, and CSF/serum quotients of Alb and IgG (QAlb, QIgG) were used to reflect the BBB status. Patients were followed up until December 2020. Cox regression and Kaplan-Meier method were used for survival analysis.
RESULTS: The CSF-TP, CSF-Alb, and CSF-IgG concentrations were significantly higher in patients than controls (p < 0.01). Increased CSF-TP and CSF-IgG was found in 45 (39.8%) and 27 (23.9%) ALS patients, while in 7 (58.3%) and 5 (41.7%) ALS-FTD patients. The level of CSF-Alb, CSF-IgG, and CSF-MBP were significantly higher in patients with ALS-FTD than ALS. MBP showed a moderate accuracy in the distinction between ALS-FTD and ALS (AUC = 0.715 ± 0.101). No difference in MBP was found between patients and controls. Kaplan-Meier analysis indicated that a higher CSF-TP, CSF-IgG, QIgG, or QAlb was significantly associated with shorter survival. Cox regression model showed that CSF-TP, CSF-IgG, and QIgG were independent predictors of survival.
CONCLUSION: Our findings suggested that BBB dysfunction was more prominent in ALS-FTD than ALS and associated with a worse prognosis. Further studies are needed to determine the role of CSF-MBP as a biomarker in ALS.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Blood–brain barrier; Frontotemporal dementia; Myelin basic protein

Mesh:

Substances:

Year:  2021        PMID: 34826032     DOI: 10.1007/s10072-021-05731-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  37 in total

1.  Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis.

Authors:  Shoichi Sasaki
Journal:  Neuropathology       Date:  2015-08-04       Impact factor: 1.906

Review 2.  Myelin basic protein: a multifunctional protein.

Authors:  J M Boggs
Journal:  Cell Mol Life Sci       Date:  2006-09       Impact factor: 9.261

Review 3.  Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis.

Authors:  Mariana Pehar; Benjamin A Harlan; Kelby M Killoy; Marcelo R Vargas
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 4.  FTD and ALS: a tale of two diseases.

Authors:  R Ferrari; D Kapogiannis; E D Huey; P Momeni
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

Review 5.  Blood-Brain Barrier: From Physiology to Disease and Back.

Authors:  Melanie D Sweeney; Zhen Zhao; Axel Montagne; Amy R Nelson; Berislav V Zlokovic
Journal:  Physiol Rev       Date:  2019-01-01       Impact factor: 37.312

Review 6.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

7.  Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice.

Authors:  Ethan A Winkler; Jesse D Sengillo; Abhay P Sagare; Zhen Zhao; Qingyi Ma; Edward Zuniga; Yaoming Wang; Zhihui Zhong; John S Sullivan; John H Griffin; Don W Cleveland; Berislav V Zlokovic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

8.  Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Authors:  I Niebroj-Dobosz; P Janik; B Sokołowska; H Kwiecinski
Journal:  Eur J Neurol       Date:  2009-10-01       Impact factor: 6.089

9.  Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis.

Authors:  J Saul; E Hutchins; R Reiman; M Saul; L W Ostrow; B T Harris; K Van Keuren-Jensen; R Bowser; N Bakkar
Journal:  Acta Neuropathol Commun       Date:  2020-06-26       Impact factor: 7.801

10.  The microglial component of amyotrophic lateral sclerosis.

Authors:  Benjamin E Clarke; Rickie Patani
Journal:  Brain       Date:  2020-12-02       Impact factor: 13.501

View more
  2 in total

Review 1.  Taking Advantages of Blood-Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?

Authors:  Hugo Alarcan; Yara Al Ojaimi; Debora Lanznaster; Jean-Michel Escoffre; Philippe Corcia; Patrick Vourc'h; Christian R Andres; Charlotte Veyrat-Durebex; Hélène Blasco
Journal:  J Pers Med       Date:  2022-06-29

2.  Elevated Cerebrospinal Fluid Proteins and Albumin Determine a Poor Prognosis for Spinal Amyotrophic Lateral Sclerosis.

Authors:  Abdelilah Assialioui; Raúl Domínguez; Isidro Ferrer; Pol Andrés-Benito; Mónica Povedano
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.